Advertisement FDA approves Asmanex Twisthaler for asthma - Pharmaceutical Business review
Pharmaceutical Business review is using cookies

ContinueLearn More
Close

FDA approves Asmanex Twisthaler for asthma

Schering-Plough has said that the FDA has approved Asmanex Twisthaler 110mcg for the maintenance treatment of asthma as a preventive therapy in patients who are four to 11 years old.

Asmanex (mometasone furoate inhalation powder) is an inhaled corticosteroid (ICS). Continual use of Asmanex helps manage asthma symptoms in patients with persistent asthma. Additionally, its automatic dose counter helps patients track remaining doses.

Robert Spiegel, chief medical officer and senior vice president, Schering-Plough Research Institute, said: “As the first inhaled corticosteroid that is approved for once-daily dosing in children as young as age four, the approval of the pediatric indication for Asmanex provides an important treatment option for children with moderate and mild persistent asthma.”